Translational Development Acquisition Corp. SEC filings TDAC
Translational Development Acquisition Corp. has 80 filings in SEC EDGAR's recent list, going back to Jun 13, 2022. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Jul 27, 2026 (material agreement, unregistered share sale). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-K/A | Amended annual report | May 11, 2026 | Dec 31, 2025 |
| 10-K/A | Amended annual report | May 6, 2026 | Dec 31, 2025 |
| 10-K | Annual report | Mar 30, 2026 | Dec 31, 2025 |
| 10-K | Annual report | Mar 31, 2025 | Dec 31, 2024 |
Showing 4 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Blank Checks (SIC 6770)
- Listed as
- TDAC (Nasdaq), TDACU (Nasdaq), TDACW (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1926599
Other Blank Checks companies
- Drugs Made In America Acquisition II Corp. DMII
- EQV Ventures Acquisition Corp. II EVAC
- Bain Capital GSS Investment Corp. BCSS
- Cantor Equity Partners IV, Inc. CEPF
- Churchill Capital Corp XII CXII
- American Exceptionalism Acquisition Corp. A AEXA
- New America Acquisition I Corp. NWAX
- Ares Acquisition Corp III AAC
Source: SEC EDGAR filings. This is company-reported data, not investment advice.